Cluster headacheMANAGEMENT

NEUROLOGICAL PRESENTATIONS · 12 SECTIONS

⚲

621 items

☷ Legend

01Approach to the Critical Patient/attcp62

Immediate risks and red flags

›Time-sensitive threats

›Thunderclap onset or peak intensity within 1 minute

›Subarachnoid hemorrhage concern

›Cervical artery dissection concern

›New focal neurologic deficit

›Stroke concern

›Intracranial mass concern

›Fever or meningismus

›Meningitis or encephalitis concern

›Intracranial abscess concern

›Eye pain with vision change

›Acute angle-closure glaucoma concern

›Optic neuritis concern

›Immunocompromised state

›Opportunistic infection concern

›Intracranial lesion concern

›Pregnancy or postpartum

›Cerebral venous thrombosis concern

›Preeclampsia or eclampsia concern

›Age > 50 with new headache pattern

›Giant cell arteritis concern

›Intracranial lesion concern

›Autonomic instability or hypoxia

›Pulse oximetry < 92% on room air

›Supplemental oxygen pathway

›Alternate diagnosis pathway

›Recurrent vomiting with dehydration

›IV access and antiemetic pathway

›Electrolyte assessment pathway

Rapid syndrome confirmation

›Cluster headache pattern

›Strictly unilateral orbital or supraorbital or temporal pain

›Severe intensity

›Duration 15 to 180 minutes untreated

›Ipsilateral cranial autonomic features

›Conjunctival injection or lacrimation

›Nasal congestion or rhinorrhea

›Eyelid edema

›Forehead or facial sweating

›Miosis or ptosis

›Prominent restlessness or agitation

›Pacing or inability to lie still

›Distinguishes from migraine quiet preference

›Attack periodicity

›1 every other day to 8 per day

›Circadian and circannual clustering

Immediate monitoring and escalation

›Monitoring bundle

›Vital signs and pain score trend

›Severe pain with repeated attacks

›Response to abortive therapy

›Cardiac monitoring when vasoactive agents used

›Triptan risk factors

›Verapamil titration context

›Escalation triggers

›Any red flag feature

›Secondary headache workup pathway

›Neurology or ophthalmology consultation pathway

›Persistent severe pain after first-line abortive therapy

›Second-line abortive pathway

›Occipital nerve block consideration

›Atypical presentation or first episode

›MRI brain with pituitary focus consideration

›Alternative trigeminal autonomic cephalalgia consideration

02History/hx72

Attack characterization

›Core phenotype

›Laterality

›Side-locked unilateral attacks

›Rare side shift between bouts

›Location

›Orbital

›Supraorbital

›Temporal

›Duration

›15 to 180 minutes untreated

›Shorter duration with effective abortive therapy

›Frequency

›1 every other day to 8 per day

›Nocturnal predominance

›Associated features

›Cranial autonomic symptoms on pain side

›Tearing or red eye

›Nasal congestion or rhinorrhea

›Restlessness or agitation

›Pacing

›Rocking

›Migrainous features

›Photophobia

›Phonophobia

Triggers, exposures, and patterning

›Predictable triggers

›Alcohol during active bout

›Rapid attack provocation

›Abstinence counseling relevance

›Strong odors or solvents

›Attack provocation

›Workplace exposure relevance

›Nitroglycerin exposure

›Attack provocation

›Medication reconciliation relevance

›Temporal pattern

›Circadian timing

›Same time daily pattern

›Sleep-related attacks

›Cluster bout duration

›Weeks to months typical episodic pattern

›Remission periods for episodic phenotype

›Chronicity

›Remission absent or < 3 months over 1 year

›Preventive strategy relevance

Risk factors, comorbidities, and safety

›Primary headache history

›Prior cluster bouts

›Past effective abortive therapy

›Past preventive regimen

›Migraine history

›Coexisting migraine possibility

›Medication interaction planning

›Cardiovascular risk and contraindications

›Coronary artery disease history

›Triptan contraindication context

›Alternative abortive planning

›Uncontrolled hypertension

›Triptan risk context

›Verapamil monitoring context

›Substance and medication history

›Tobacco use

›Higher prevalence association

›cessation counseling relevance

›Medication overuse

›Frequent analgesic use

›Rebound headache overlap

›Functional impact and safety concerns

›Sleep disruption

›Nocturnal attacks

›daytime impairment

›Severe distress

›Need for supportive environment

›Mental health support resources

03Physical Exam/exam41

Focused neurologic and autonomic exam

›Neurologic screen

›Mental status

›Confusion as secondary headache signal

›Postictal features alternative diagnosis

›Cranial nerves

›Pupillary asymmetry pattern

›Extraocular movements and diplopia

›Motor and sensory exam

›New focal deficit red flag

›Unilateral weakness concern

›Autonomic features confirmation

›Eye findings

›Conjunctival injection

›Lacrimation

›Nasal findings

›Rhinorrhea

›Congestion

›Horner syndrome features

›Ptosis

›Miosis

Head, neck, eye, and vascular exam

›Eye and vision screen

›Visual acuity change

›Acute glaucoma concern

›Optic pathology concern

›Pupillary reactivity

›Fixed mid-dilated pupil concern

›Relative afferent pupillary defect concern

›Neck and temporal artery

›Meningeal signs

›Fever context

›Infection concern

›Temporal artery tenderness

›Age > 50 context

›Giant cell arteritis concern

›Blood pressure and vascular

›Hypertensive emergency signs

›End-organ findings

›Secondary headache concern

›Carotid bruit

›Vascular disease context

›Dissection context when neck pain present

04Differential Diagnosis/ddx41

Trigeminal autonomic cephalalgias and mimics

›Primary trigeminal autonomic cephalalgias

›Cluster headache (ICD-10 G44.0)

›Episodic cluster headache (ICD-10 G44.01)

›Chronic cluster headache (ICD-10 G44.02)

›Paroxysmal hemicrania

›Shorter attacks 2 to 30 minutes

›Absolute indomethacin response

›SUNCT or SUNA

›Very short attacks seconds to minutes

›Prominent conjunctival injection and tearing

›Common mimics

›Migraine without aura (ICD-10 G43.0)

›Longer duration 4 to 72 hours

›Preference for rest and darkness

›Trigeminal neuralgia (ICD-10 G50.0)

›Electric shock quality

›Triggered by touch or chewing

Secondary causes of unilateral orbital or temporal pain

›Vascular and hemorrhagic

›Subarachnoid hemorrhage (ICD-10 I60)

›Thunderclap onset

›Neck stiffness or altered mental status

›Cervical artery dissection (ICD-10 I77.74)

›Neck pain

›Partial Horner syndrome

›Cerebral venous thrombosis (ICD-10 I67.6)

›Pregnancy or postpartum

›Papilledema

›Eye and ENT

›Acute angle-closure glaucoma (ICD-10 H40.21)

›Vision loss halos

›Mid-dilated pupil

›Acute sinusitis with orbital pain (ICD-10 J01)

›Fever

›Purulent nasal discharge

›Structural and inflammatory

›Pituitary lesion or apoplexy (ICD-10 E23.6)

›Ophthalmoplegia

›Visual field deficit

›Intracranial mass (ICD-10 D49.6)

›Progressive course

›New neurologic findings

05Laboratory Tests/lt35

Baseline tests when atypical or secondary concern

›Screening labs for red flags

›Complete blood count for infection or anemia concern

›Leukocytosis context

›Severe anemia alternative explanation

›Electrolytes for dehydration or vomiting

›Sodium mmol/L abnormality and confusion risk

›Potassium mmol/L abnormality and arrhythmia risk

›Creatinine for imaging contrast planning

›Contrast CT angiography eligibility

›Medication dosing considerations

›Inflammatory labs when indicated

›ESR for giant cell arteritis concern

›Age > 50 context

›Temporal artery tenderness context

›CRP for giant cell arteritis concern

›Elevated inflammatory signal

›Combined interpretation with ESR

Medication-specific monitoring labs

›Lithium safety labs

›Creatinine and eGFR baseline

›Lithium clearance dependence

›Toxicity risk with renal impairment

›TSH baseline and follow-up

›Hypothyroidism risk

›Fatigue and weight change confounders

›Corticosteroid risk context

›Glucose mmol/L when diabetes risk

›Hyperglycemia risk

›Symptom confounding

Pregnancy-related testing

›Pregnancy status assessment

›Urine or serum beta-hCG when status uncertain

›Imaging pathway selection

›Medication safety selection

›Preeclampsia screen when headache with hypertension

›Urine protein assessment context

›End-organ symptom review context

06Diagnostic Tests/dt61

Scoring Systems

›Diagnostic criteria framework

›ICHD-3 cluster headache criteria mapping

›Severe unilateral orbital or supraorbital or temporal pain

›Duration 15 to 180 minutes untreated

›Frequency 1 every other day to 8 per day

›Ipsilateral cranial autonomic symptoms or restlessness

›Episodic versus chronic phenotype

›Episodic with remission periods

›Chronic with remission absent or < 3 months over 1 year

›Red flag screen framework

›Secondary headache risk features

›New neurologic deficit

›Thunderclap onset

›Low threshold imaging for first presentation

›First cluster-like attack

›Atypical autonomic or neurologic signs

MRI

›MRI brain with and without contrast

›Indications

›First presentation of cluster-like headache

›Atypical features or abnormal neurologic exam

›Protocol emphasis

›Pituitary and parasellar region attention

›Cavernous sinus evaluation

›Key secondary targets

›Pituitary lesion

›Carotid cavernous fistula or cavernous sinus pathology

›MRA head and neck

›Indications

›Neck pain or Horner syndrome concern

›Dissection risk factors

›Interpretation pearls

›Flow limitation or mural hematoma

›Correlation with focal neurologic deficits

›Non-contrast CT head

›Indications

›Thunderclap onset

›Altered mental status

›Limitations

›Normal CT does not exclude all secondary causes

›MRI often preferred for pituitary and parasellar disease

›CT angiography head and neck

›Indications

›Dissection concern

›Sentinel bleed concern with high-risk features

›Contraindications and cautions

›Iodinated contrast allergy history

›Significant renal impairment

Ultrasound (or US)

›Ocular ultrasound when eye emergency concern

›Indications

›Vision loss with eye pain

›Posterior segment pathology concern

›Limitations

›Does not rule out acute angle-closure glaucoma

›Needs correlation with intraocular pressure testing

›Temporal artery ultrasound when giant cell arteritis concern

›Indications

›Age > 50 with new headache and jaw claudication

›Elevated ESR or CRP

›Findings

›Halo sign

›Segmental stenosis

07Disposition/dispo38

Admission, observation, and consult pathways

›Admission indications

›Secondary headache concern

›Abnormal neurologic exam

›Persistent severe pain with inadequate outpatient control

›Frequent attacks with inability to manage at home

›Multiple daily attacks despite abortive therapy

›Need for inpatient bridge therapy

›Observation indications

›First-time cluster-like headache with stable exam

›Completion of imaging pathway

›Response assessment after abortive therapy

›Medication initiation requiring monitoring

›Verapamil with ECG monitoring plan

›Lithium initiation risk context

›Consultation triggers

›Neurology

›Diagnostic uncertainty or atypical features

›Preventive initiation and titration plan

›Ophthalmology

›Eye pain with vision change

›Suspected acute glaucoma

Discharge criteria and follow-up

›Discharge criteria

›Red flags absent

›Normal neurologic exam

›Imaging completed when indicated

›Abortive plan established

›Home oxygen access plan when available

›Triptan plan with contraindications reviewed

›Preventive or bridge plan initiated or arranged

›Verapamil start plan

›Prednisone bridge plan when appropriate

›Follow-up timing

›Neurology or headache clinic

›Within 1 to 2 weeks for new diagnosis

›Earlier if daily attacks persist

›Primary care

›Cardiovascular risk review for triptan eligibility

›Smoking cessation support

08Treatment/t144

Acute abortive therapy

›Oxygen therapy

›High-flow oxygen

›Non-rebreather mask

›Flow 12 to 15 L/min

›Duration 15 to 20 minutes or until pain relief

›Demand-valve system when available

›Higher inspired oxygen fraction

›Faster onset in some patients

›Safety and practicality

›Smoking prohibition during oxygen use

›Fire risk

›Clear instructions for home use

›COPD with CO2 retention risk

›Close monitoring if significant baseline hypercapnia

›Alternate abortive option availability

›Triptans

›Sumatriptan 6 mg subcutaneous

›Onset typically within minutes

›Preferred for rapid severe attacks

›Repeat dosing constraints per local policy

›Contraindications

›Ischemic heart disease

›Uncontrolled hypertension

›Zolmitriptan intranasal 5 to 10 mg

›Option when injection not tolerated

›Faster than oral route

›Useful for home administration

›Contraindications

›Significant cardiovascular disease

›Hemiplegic or basilar migraine history concern

›Intranasal local anesthetic

›Lidocaine intranasal 4% to 10%

›Sphenopalatine region targeting

›Short-term relief in some patients

›Adjunct to oxygen or triptan

›Adverse effects

›Numbness and bitter taste

›Aspiration risk if excessive posterior drip

›Antiemetic and rescue options

›Metoclopramide 10 mg IV

›Nausea control

›Adjunct when migrainous features prominent

›Hydration synergy

›Adverse effects

›Akathisia

›Dystonia

›Dihydroergotamine IV or IM or nasal

›Specialty or protocol-dependent use

›Contraindicated in vascular disease

›Avoid with recent triptan use per protocol

Transitional therapy

›Corticosteroid bridge

›Prednisone oral taper

›Typical starting range 40 to 60 mg daily

›Short course 5 to 10 days then taper

›Bridge until preventive effective

›Risks

›Hyperglycemia

›Mood and sleep disturbance

›Occipital nerve steroid injection

›Greater occipital nerve block

›Short-term reduction in attack frequency

›Useful when systemic steroids undesirable

›Local risks

›Bleeding or infection

›Temporary numbness

Preventive therapy

›Verapamil

›Immediate-release or sustained-release regimens

›Typical total daily range 240 to 960 mg

›Titration every 7 to 14 days based on response

›Dose division through the day

›ECG monitoring

›Baseline ECG before initiation

›Repeat ECG with dose increases for PR prolongation or heart block

›Adverse effects and interactions

›Hypotension and bradycardia

›Dizziness and syncope risk

›Avoid with significant conduction disease

›Constipation

›Preventive bowel regimen counseling

›Hydration advice

›CGRP monoclonal antibody option

›Galcanezumab 300 mg subcutaneous monthly

›Episodic cluster headache indication in some jurisdictions

›Not established for chronic cluster headache

›Insurance and access planning

›Adverse effects

›Injection site reactions

›Hypersensitivity rare

›Lithium

›Typical dosing 300 mg 2 to 3 times daily

›Serum level target protocol-dependent

›Narrow therapeutic index

›Toxicity risk with dehydration

›Monitoring

›Serum lithium level timing per protocol

›Renal and thyroid monitoring schedule

›Contraindications and cautions

›Significant renal impairment

›Accumulation risk

›Alternative preventive preferred

›Drug interactions

›NSAIDs increasing lithium level risk

›ACE inhibitors and diuretics increasing lithium level risk

›Topiramate

›Typical dosing 25 mg nightly with gradual titration

›Target range often 100 to 200 mg daily

›Slow titration to reduce cognitive side effects

›Hydration counseling for stone risk

›Adverse effects

›Paresthesias

›Cognitive slowing

›Melatonin

›9 to 10 mg nightly

›Circadian pattern relevance

›Night attack reduction in some patients

›Low-risk adjunct

›Adverse effects

›Daytime sleepiness

›Vivid dreams

Evidence and recommendation tags

›Abortive therapy evidence tags

›High-flow oxygen supported by guideline consensus

›Rapid onset and favorable safety profile

›Practical access limitations common

›Subcutaneous sumatriptan supported by guideline consensus

›Rapid relief for severe attacks

›Cardiovascular contraindication screening required

›Preventive therapy evidence tags

›Verapamil first-line preventive in guideline consensus

›ECG monitoring required due to conduction risk

›Dose titration often necessary

›Corticosteroid bridge supported by expert consensus

›Short-term reduction in attack frequency

›Not a long-term preventive

›Emergency medicine policy mapping

›ACEP clinical policy structure applied to acute headache evaluation

›Level B for imaging when red flags present

›Level C for shared decision-making when low-risk presentation

›Cardiology style recommendation mapping

›Class I style recommendation for oxygen and triptan as first-line abortive in typical cluster without contraindications

›Based on specialist guideline consensus

›Patient-specific risk screening required

›Class IIa style recommendation for occipital nerve block as transitional therapy

›Useful when systemic steroids undesirable

›Procedure availability dependent

09Special Populations/sp30

Pregnancy

›Pregnancy considerations

›Diagnostic approach

›Low threshold secondary cause evaluation in pregnancy and postpartum

›MRI preferred when imaging needed and feasible

›Abortive therapy safety

›Oxygen generally preferred

›Triptan risk-benefit individualized and protocol-dependent

›Preventive and bridge therapy cautions

›Verapamil use requires maternal ECG considerations

›Corticosteroid short course risk-benefit individualized

Geriatric

›Older adult considerations

›Secondary cause prevalence higher

›Imaging threshold lower for new cluster-like headache

›Giant cell arteritis screening when appropriate

›Medication risk

›Triptan cardiovascular contraindications more common

›Verapamil conduction disease and polypharmacy interactions

›Disposition planning

›Falls risk with hypotension from verapamil

›Close follow-up for medication titration

Pediatrics

›Pediatric considerations

›Diagnostic confidence

›Cluster headache rare in children

›Secondary cause evaluation threshold lower

›Treatment adaptation

›Oxygen as preferred abortive when diagnosis confident

›Triptan dosing and age approvals protocol-dependent

›Specialist coordination

›Pediatric neurology involvement early

›School and sleep disruption planning

10Background/b48

Epidemiology

›Frequency and demographics

›Relative rarity compared with migraine

›Often underdiagnosed or misdiagnosed

›Delay to diagnosis common

›Sex distribution

›Male predominance reported in many cohorts

›Female cases under-recognized risk

›Typical age of onset

›Early adulthood common

›Late onset prompts secondary evaluation

Pathophysiology

›Trigeminal autonomic reflex activation

›Trigeminal nociceptive pathways

›Severe orbital and temporal pain pathway

›Trigeminal distribution localization

›Parasympathetic outflow via sphenopalatine ganglion

›Lacrimation and nasal congestion

›Conjunctival injection

›Sympathetic dysfunction

›Partial Horner syndrome features

›Ptosis and miosis on affected side

›Hypothalamic involvement

›Circadian and circannual periodicity

›Attacks at consistent times

›Bout seasonality

›Sleep relationship

›Nocturnal attacks

›REM association hypothesis

Therapeutic Considerations

›Oxygen mechanism rationale

›Cerebral vasoconstriction and neurochemical modulation hypotheses

›Rapid symptomatic relief pathway

›Minimal systemic adverse effects

›Delivery and flow importance

›High inspired oxygen fraction requirement

›Early initiation improves response

›Triptan mechanism rationale

›Serotonin receptor agonism

›Trigeminal pathway modulation

›Neurogenic inflammation reduction

›Route selection rationale

›Subcutaneous fastest onset

›Intranasal alternative when injection not feasible

›Preventive rationale

›Verapamil calcium channel blockade

›Attack frequency reduction in many patients

›Dose-response with monitoring constraints

›Transitional therapy bridge

›Steroid short course to suppress attacks

›Preventive onset delay coverage

11Patient Discharge Instructions/pdi25

copy discharge instructions

›Discharge instructions

›Diagnosis explanation

›Cluster headache pattern with severe one-sided attacks and tearing or nasal symptoms

›Bouts can last weeks to months with multiple attacks per day

›Home abortive plan

›Oxygen use plan if prescribed

›Triptan use plan if prescribed and safe

›Trigger avoidance during bout

›Alcohol avoidance during active cluster period

›Strong odor and solvent avoidance when possible

›Preventive and bridge plan

›Verapamil schedule and ECG monitoring plan if started

›Steroid taper instructions if prescribed

›Return now or call emergency services

›Sudden worst headache of life or thunderclap onset

›Weakness, numbness, speech trouble, confusion, fainting, or seizure

›Fever with stiff neck

›Eye pain with vision loss or new severe redness

›New headache pattern after age 50

›Follow-up

›Neurology or headache clinic appointment timing

›Primary care review for cardiovascular risk and medication safety

›Safety and support

›Severe distress or inability to cope

›Seek immediate help from trusted adult or local emergency services

12References/r24

Clinical guidelines and consensus sources

›Guideline sources

›International Classification of Headache Disorders, 3rd edition diagnostic criteria

›Cluster headache diagnostic criteria

›Episodic and chronic cluster definitions

›American Headache Society guidance on cluster headache management

›High-flow oxygen as first-line abortive

›Subcutaneous sumatriptan as first-line abortive

›European Headache Federation guidance on trigeminal autonomic cephalalgias

›Verapamil as first-line preventive

›Transitional steroid and occipital nerve block options

›Emergency medicine policy sources

›ACEP clinical policy framework for acute headache evaluation

›Imaging triggers for red flag features

›Risk stratification principles for secondary headache

Evidence-based sources and key therapies

›Therapy evidence anchors

›Oxygen trials and observational evidence base

›Rapid relief compared with room air in many patients

›Optimal delivery with high flow and non-rebreather

›Triptan clinical trial evidence base

›Subcutaneous sumatriptan rapid efficacy

›Intranasal zolmitriptan efficacy as alternative

›Preventive therapy evidence base

›Verapamil dose titration with ECG monitoring necessity

›Lithium and topiramate as alternatives when verapamil insufficient

Learn More: Cluster headache→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.